Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab + Carboplatin + Paclitaxel in Untreated Advanced Mucosal Melanoma
NCT02023710Phase 2Unknown
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Dec 2013
- Primary completion
- Dec 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in mucosal melanoma (MM), sponsored by Peking University Cancer Hospital & Institute. Status: unknown.
02
Drugs
bevacizumab
03
Conditions
mucosal melanoma (MM)
Beyond the preview
Go deeper on NCT02023710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02023710.